Administration of anti-cytokine f(ab')2 antibody fragments

• US 20060210563A1
• Filed: 07/25/2003
• Published: 09/21/2006
• Est. Priority Date: 07/25/2003
• Status: Abandoned Application

• Current Assignee: Alberto Diaz-Quinonez, Jorge F. Panlagua-Solis, Juan Lopez De Silanes, Rita G. Mancilla-Nava
• Original Assignee: Alberto Diaz-Quinonez, Jorge F. Panlagua-Solis, Juan Lopez De Silanes, Rita G. Mancilla-Nava
• Inventors: Panlagua-Solis, Jorge F., Diaz-Quinonez, Alberto, Mancilla-Nava, Rita G., Lopez De Silanes, Juan
• Application Number:
  US10/565,885
• Publication Number:
  US 20060210563A1
• Time in Patent Office: Days
• US Class Current: 424/145.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C07K 16/241 Tumor Necrosis Factors
• CPC Class Codes: C07K 16/249 Interferons

Abstract

The present invention is directed to a method of treating a cytokine-mediated immune reaction in a patient in need of such treatment by administration of an effective amount of anti-cytokine F(ab′)2 antibody fragments. The antibody fragments are preferably free from albumin and of whole antibodies, as well as substantially free of pyrogens. The anti-cytokine F(ab′)2 antibody fragments may be administered with an effective amount of a pharmaceutically acceptable carrier.

Claims

1. A method for treating cytokine-mediated immune reactions in a human which comprises:

topically administering to a human in need of such treatment an effective amount of anti-cytokine F(ab′

)₂ antibody fragments.

2. The method of claim 1, wherein said cytokine-mediated immune reaction comprises a T cell-mediated inflammatory disease.

3. The method of claim 2, wherein said T cell-mediated inflammatory disease comprises psoriasis vulgaris.

4. The method of claim 1, wherein said cytokine-mediated immune reaction comprises a chronic inflammatory disease.

5. The method of claim 4, wherein said chronic inflammatory disease comprises rheumatoid arthritis.

6. The method of claim 1, wherein the cytokine-mediated immune reaction comprises septic shock.

7. The method of claim 1, wherein the cytokine-mediated immune reaction comprises rejection of a prosthetic or tissue transplant.

8. The method of claim 1, wherein said anti-cytokine F(ab′

)₂ antibody fragments are applied in combination with a dermatologically acceptable carrier.

9. The method of claim 1, wherein said anti-cytokine F(ab′

)₂ antibody fragments are substantially free of albumin, whole antibodies, and/or pyrogens.

10. The method of claim 9, wherein said anti-cytokine F(ab′

)₂ antibody fragments are administered in combination with a dermatologically acceptable carrier.

11. The method of any of claims 1-10, wherein said cytokine is alpha tumor necrosis factor (TNF-α

).

12. The method of any of claims 1-10, wherein said cytokine is an interleukin.

13. The method of claim 12, wherein said cytokine is interleukin-1 (IL-1).

14. The method of claim 12, wherein said interleukin is interleukin-1 alpha (IL-1α

).

15. The method of claim 12, wherein said interleukin is interleukin-1 beta (IL-1β

).

16. The method of claim 12, wherein said interleukin is interleukin-2 (IL-2).

17. The method of claim 12, wherein said interleukin is interleukin-6 (IL-6).

18. The method of claim 12, wherein said interleukin is interleukin-12 (IL-12).

19. The method of any of claims 1-10, wherein said cytokine is gamma interferon (IFN-γ

).